Acute anterior uveitis in the year before the first TNF inhibitor and during 1 year of golimumab treatment.
| Before the First TNFi | During Golimumab TX | 95% CI | |
|---|---|---|---|
| Observational years1 | 93 | 93 | |
| Years at risk for a new AAU2 | 89.8 | 90.4 | |
| No. patients with AAU | 7 | 2 | * |
| No. AAU attacks | 10 | 2 | |
| AAU attacks/100 years at risk3 | 11.1 | 2.2 | |
| Rate-ratio of new AAU (95% CI) | 0.2 | (0.04–0.91) |
Values are reported as numbers, numbers per 100 patient years, and ratio with 95% CI.
↵* Nonsignificant reduction.
↵1 The total no. patient-years observed during the study.
↵2 The no. observational years minus the period that AAU was present.
↵3 The no. AAU attacks per 100 patient-years at risk for new AAU. AAU: acute anterior uveitis; TNFi: tumor necrosis factor inhibitor; TX: treatment.